<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283149</url>
  </required_header>
  <id_info>
    <org_study_id>CP19-01</org_study_id>
    <nct_id>NCT04283149</nct_id>
  </id_info>
  <brief_title>Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)</brief_title>
  <official_title>A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staar Surgical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Staar Surgical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This objective of this study is to evaluate the safety, and to collect supportive data on
      effectiveness of the EVO/EVO+ Visian® Implantable Collamer® Lens (ICL) in study participants
      who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be
      evaluated when 300 primary eyes complete 6 months of follow-up. Final study analysis will be
      assessed when all treated eyes complete 36 months of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at up to 20 clinical sites in the United States by surgeons
      qualified by training and experience to implant STAAR ICLs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled eyes will undergo phakic eye surgery to have one of the available implantable collamer lenses EVO or EVO+ (spherical or toric) ICL implanted in their primary eye. Fellow eye surgery will occur between 7 and 14 days after primary eye surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of peripheral iridotomy (PI) in Primary Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of PI required to treat elevated intraocular pressure (IOP) caused by mechanical pupillary block in primary eyes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Cell Density (ECD) Loss in Primary Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Distribution of percent ECD losses and the percent of eyes that have ECD &lt;1500 and ECD &lt;1000 in primary eyes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) in Primary Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of peripheral iridotomy (PI) in Primary and Fellow Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of PI required to treat elevated intraocular pressure (IOP) caused by mechanical pupillary block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Density (ECD) Loss in Primary and Fellow Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Distribution of percent ECD losses and the percent of eyes that have ECD &lt;1500 and ECD &lt;1000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) in all Treated Eyes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">333</enrollment>
  <condition>Myopia</condition>
  <condition>Myopic Astigmatism</condition>
  <arm_group>
    <arm_group_label>EVO ICL Surgery for Myopia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects with myopia will undergo ICL surgery in one or both eyes with EVO MICL model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVO+ ICL Surgery for Myopia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ MICL model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVO TICL Surgery for Myopia with Astigmatism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO TICL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVO+ TICL Surgery for Myopia with Astigmatism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ TICL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVO Visian ICL for Myopia</intervention_name>
    <description>The EVO MICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.</description>
    <arm_group_label>EVO ICL Surgery for Myopia</arm_group_label>
    <other_name>VICMO</other_name>
    <other_name>EVO MICL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVO Visian Toric ICL for Myopia with Astigmatism</intervention_name>
    <description>The EVO TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.</description>
    <arm_group_label>EVO TICL Surgery for Myopia with Astigmatism</arm_group_label>
    <other_name>VTICMO</other_name>
    <other_name>EVO TICL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVO+ Visian ICL for Myopia</intervention_name>
    <description>The EVO+ MICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.</description>
    <arm_group_label>EVO+ ICL Surgery for Myopia</arm_group_label>
    <other_name>VICM5</other_name>
    <other_name>EVO+ ICL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVO+ Visian Toric ICL for Myopia with Astigmatism</intervention_name>
    <description>The EVO+ TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.</description>
    <arm_group_label>EVO+ TICL Surgery for Myopia with Astigmatism</arm_group_label>
    <other_name>VTICM5</other_name>
    <other_name>EVO+ TICL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to high myopia or myopic astigmatism correctable with available EVO/EVO+ ICL
             powers.

          -  Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE)
             for 1 year prior to implantation.

          -  Able and willing to return for scheduled follow-up examinations after surgery.

          -  Able to read, understand and provide written informed consent on the Institutional
             Review Board (IRB)-approved informed consent form (ICF) and provide authorization as
             appropriate for local privacy regulations.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Insulin-dependent diabetes or diabetic retinopathy.

          -  History of previous ocular surgery.

          -  Cataract of any grade.

          -  Monocular.

          -  Pregnant or nursing women, or those who plan to become pregnant over the course of
             this clinical study.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Hayashida, OD., FAAO</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Clinical and Medical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Egamino, PhD</last_name>
    <phone>(626) 303-7902</phone>
    <phone_ext>2215</phone_ext>
    <email>ClinicalAffairs@staar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Weinmann, MSc</last_name>
    <phone>(626) 303-7902</phone>
    <phone_ext>2215</phone_ext>
    <email>ClinicalAffairs@staar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnett Dulaney Perkins</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>602-598-7646</phone>
      <email>pcrincoli@bdpec.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aloha Laser Vision, LLC</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>808-792-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Price Vision Group,</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>317-844-5530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>913-234-6347</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solomon Eye Physicians and Surgeons/Bowie Vision Institute</name>
      <address>
        <city>Bowie</city>
        <state>Maryland</state>
        <zip>20716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>301-464-1885</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brinton Vision</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>314-375-2020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kugler Vision, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>402-558-2211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>216-503-6535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kremer Eye Center</name>
      <address>
        <city>King Of Prussia</city>
        <state>Pennsylvania</state>
        <zip>19406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>732-750-0403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>605-361-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>214-220-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkhurst NuVision</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>201-585-2020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision/Hoopes, Durrie, Rivera Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>801-988-7346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CP19-01 Study Coordinator</last_name>
      <phone>801-263-5735</phone>
      <email>ladams@theeyeinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>CP19-01 Study Coordinator</last_name>
      <email>abagley@theeyeinstitute.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nearsightedness</keyword>
  <keyword>Phakic intraocular lens (IOL)</keyword>
  <keyword>ICL</keyword>
  <keyword>Toric ICL</keyword>
  <keyword>EVO</keyword>
  <keyword>EVO+</keyword>
  <keyword>Visian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

